OakChart

PTC Therapeutics Inc

PTCTHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:10 PM ET

64.61+0.47 (0.73%)
2026-11-11 21:11 CET
Market cap
5,358.53 USD m
Revenue, TTM
1,155.55 USD m
Net income, TTM
-105.97 USD m
Free cash flow, TTM
2.07 USD m
EPS diluted, TTM
-1.41
P/E
-
Compare

Price

PTCT against its 20, 50 and 200-day averages
2050200beatmiss
60.0070.0080.0090.003.4M6.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PTCTclose 64.6120-day 63.2250-day 64.44200-day 70.2964.6152w high52w low

28.9% under the 52-week high of 90.87 on 9 Jul 2026. 52-week low 58.80 on 14 Oct 2026. Last 15 sessions, 18.5% high to low

Volume 0.33× normal · the line is the 50-bar volume average

Profile

PTCT
52-week range, 18% of the way up
58.8090.87

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

IndexRUT
Employees991
IPOJun 20, 2013
Beta0.50
ATR, 14d2.62
Rel volume0.33
Short float9.61%
Insider own3.11%
Inst own119.27%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap5.40B
Enterprise Value3.91B
Income-105.97M
Sales1.16B
Book/sh-2.29
Cash/sh25.47
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees991
IPOJun 20, 2013

Ratios

P/E-
Forward P/E23.66
PEG-
P/S4.67
P/B-
P/C2.54
P/FCF2607.49
EV/EBITDA12.58
EV/Sales3.38
Quick Ratio3.13
Current Ratio3.27
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.41
EPS next Y2.73
EPS next Q0.35
EPS this Y-93.24%
EPS next Y418.98%
EPS next 5Y-17.42%
EPS past 3/5Y- -
Sales past 3/5Y35.30% 35.37%
EPS Y/Y TTM-113.73%
Sales Y/Y TTM-35.05%
EPS Q/Q-417.59%
Sales Q/Q69.57%
EarningsOct 29 AMC
EPS/Sales Surpr.-532.36% 16.77%

Ownership

Insider Own3.11%
Insider Trans-11.10%
Inst Own119.27%
Inst Trans6.95%
ROA-3.62%
ROE-
ROIC-24.61%
Gross Margin89.28%
Oper. Margin21.58%
Profit Margin-9.17%
SMA202.19%
SMA500.26%
SMA200-8.08%
Trades-

Technical

Shs Outstand83.54M
Shs Float80.95M
Short Float9.61%
Short Ratio7.18
Short Interest7.78M
52W High90.87 -28.90%
52W Low58.80 9.87%
Volatility4.08% 4.27%
ATR (14)2.62
RSI (14)51.35
Beta0.50
Rel Volume0.33
Avg Volume1.08M
Volume314,158

Performance

Perf Week-6.33%
Perf Month7.82%
Perf Quarter-10.23%
Perf Half Y-12.05%
Perf YTD-14.95%
Perf Year-12.48%
Perf 3Y248.47%
Perf 5Y62.70%
Perf 10Y471.74%
Recom1.56
Target Price100.47
Prev Close64.14
Price64.61
Change %0.73%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedTTruistHold$62-4.0%
Sep 14, 2026ResumedLLeerink PartnersOutperform$98+51.7%
Jun 09, 2026UpgradeCCitigroupNeutral → Buy$108+67.2%
May 27, 2026UpgradeJJefferiesHold → Buy$85+31.6%
May 08, 2026UpgradeTTD CowenHold → Buy$90+39.3%
Apr 10, 2026InitiatedRRaymond JamesOutperform$108+67.2%
Jan 28, 2026ResumedBBarclaysOverweight$119+84.2%
Dec 01, 2025DowngradeRRBC Capital MktsOutperform → Sector Perform$91+40.9%
Oct 20, 2025InitiatedWWells FargoOverweight$73+13.0%
Jun 17, 2025InitiatedTTruistBuy$80+23.8%

Peers

Mkt cap
TickerCompanyMkt cap
BMRNBiomarin Pharmaceutical Inc11.21B
SRPTSarepta Therapeutics Inc1.79B
RAREUltragenyx Pharmaceutical Inc1.68B
QUREuniQure NV1.68B
DYNDyne Therapeutics Inc3.39B
IONSIonis Pharmaceuticals Inc4.77B
WVEWave Life Sciences Inc671.54M
EWTXEdgewise Therapeutics Inc5.15B
MIRMMirum Pharmaceuticals Inc6.18B
CAPRCapricor Therapeutics Inc616.56M

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
SCHMERTZLER MICHAELDirectorOct 14 '26Sale59.612,500149,0371,291,594Oct 16 05:20 PM
Boulding Mark ElliottEXEC. VP AND CLOOct 09 '26Option Exercise39.421927,569105,464Oct 13 05:20 PM
Boulding Mark ElliottEXEC. VP AND CLOOct 09 '26Sale64.2619212,338105,272Oct 13 05:20 PM
SCHMERTZLER MICHAELDirectorOct 07 '26Sale63.392,500158,4801,294,094Oct 09 05:20 PM
Boulding Mark ElliottOfficerOct 09 '26Proposed Sale64.2619212,339Oct 09 04:15 PM
Boulding Mark ElliottEXEC. VP AND CLOOct 05 '26Option Exercise39.421,63864,570106,910Oct 07 05:20 PM
Boulding Mark ElliottEXEC. VP AND CLOOct 06 '26Option Exercise39.4243517,148105,707Oct 07 05:20 PM
Boulding Mark ElliottEXEC. VP AND CLOOct 05 '26Sale64.031,638104,881105,272Oct 07 05:20 PM
Boulding Mark ElliottEXEC. VP AND CLOOct 06 '26Sale64.1643527,910105,272Oct 07 05:20 PM
Section Six Partners, L.P.Affiliate of DirectorOct 07 '26Proposed Sale64.3510,000643,500Oct 07 04:37 PM
Boulding Mark ElliottOfficerOct 06 '26Proposed Sale64.1643527,908Oct 06 04:07 PM
Boulding Mark ElliottOfficerOct 05 '26Proposed Sale64.031,638104,883Oct 05 04:20 PM
STEELE GLENN JR MD PHDDirectorSep 30 '26Option Exercise11.2312,000134,76034,500Oct 02 05:20 PM
STEELE GLENN JR MD PHDDirectorSep 30 '26Sale65.1612,000781,92022,500Oct 02 05:20 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
IJTiShares S&P Small-Cap 600 Growth ETFAUM: 7.45B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B

News

latest 14 of 200
  • PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program (PR Newswire) +11.89%
  • PTC Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
  • PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.97%
  • PTC Therapeutics Crushes Estimates And Lifts Guidance Again As Sephience Scales, But Implied Q4 Step-Down And Slower US Growth Temper The Beat (Earnings Whispers)
  • PTC Therapeutics: Q3 Earnings Snapshot (Associated Press)
  • PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results (PR Newswire)
  • PTC Therapeutics Must Show Sephience-Style Momentum Holds As Shares Slide Despite Third Guidance Raise (Earnings Whispers)
  • PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026 (PR Newswire)
  • Is PTC Stock Increasing Your Market Risk? (Trefis)
  • Which Gives You More Of Hard-To-Replace Software, PTC Or Fair Isaac? (Trefis)
  • PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.23%
  • PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy (PR Newswire)
  • Own Oracle For The AI Boom? PTC's Story Looks Cleaner (Trefis)
  • PTC Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-29-0.6200.143-0.620357.81306.4315
2026Q22026-07-300.9200.2360.918360.52298.6313
2026Q12026-05-07-0.030-0.472-0.034272.55217.4212
2025Q42026-02-19-1.6700.103-1.673164.68279.4814
2025Q32025-11-040.200-1.1330.195211.01172.914
2025Q22025-08-07-0.830-1.021-0.830178.88172.316
2025Q12025-05-0610.040-1.00810.0441,176169.9312
2024Q42025-02-27-0.850-0.540-0.853213.17232.4412
2024Q32024-11-07-1.390-1.521-1.387196.79170.5914
2024Q22024-08-08-1.290-1.120-1.293186.7183.2811
2024Q12024-04-25-1.200-1.275-1.197210.12165.4912
2023Q42024-02-29-2.060-0.138-2.063307.06314.9613
2023Q32023-10-26-1.760-1.065-1.764196.58210.2313
2023Q22023-08-03-2.660-1.621-2.661213.81206.9915
2023Q12023-04-27-1.880-1.534-1.885220.38200.5215
2022Q42023-02-21-2.350-1.587-2.352167.41188.3814

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-4.270-3.135-4.274306.98305.9
2020FY-6.640-6.316-6.636380.77376.02
2021FY-7.430-6.679-7.435538.59524.98
2022FY-7.790-6.961-7.794698.8716.43
2023FY-8.370-7.087-8.373937.82943.98
2024FY-4.730-4.454-4.728806.78803.68
2025FY7.7809.5027.7801,7311,848
2026FY-0.526--1,320
2027FY-2.730--1,429
2028FY-4.381--1,631
2029FY-4.545--1,764
2030FY-5.545--1,908

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-301382330.38303.28348
2026Q4S2026-10-291421318.84286.8352.29
2026Q4S2026-10-261421318.84286.8352.29
2026Q4S2026-10-161422319286.8352.29
2026Q4S2026-10-151422319.03286.8352.29
2026Q4S2026-10-141322317.87286.8352.29
2026Q4S2026-10-131364317.87286.8352.29
2026Q4S2026-10-091264318.84286.8352.29
2026Q4S2026-10-071255318.15286.8352.29
2026Q4S2026-10-061255320.5286.8352.29
2026Q4S2026-10-031255320.5286.8352.29
2026Q4S2026-09-221265320.5286.8352.29
2026Q4S2026-09-111266320.5286.8352.29
2026Q4S2026-09-011266319.57286.8352.29

Estimate history

EPS, annual-2.016-2.75-4.274-6.636-7.435-7.794-8.373-4.7287.779-1.4082
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.387-0.85310.044-0.830.195-1.673-0.0340.918-0.619
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual194.392264.734306.98380.766538.593698.801937.822806.781730.6551155.55
Period201720182019202020212022202320242025TTM
Sales, quarterly196.786213.1721176.096178.875211.007164.677272.551360.519357.807
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual41.61250.60661.93669.71870.82873.10575.70977.70481.47483.536
Period201720182019202020212022202320242025MRQ
Shares, quarterly76.95277.70479.22579.37879.93281.47482.88283.32783.536
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,155.551,730.65806.78937.82698.80538.59380.77306.98264.73
Cost of Goods Sold Incl. D&A123.9371.75118.14288.12161.2387.0855.8339.7835.55
Gross Profit1,031.621,658.90688.64649.70537.57451.51324.93267.19229.19
Selling, General and Administrative Excl. Other786.67814.59835.39999.10977.49826.46627.41459.99325.53
Research and Development438.50455.25534.48666.56651.50540.68382.94257.45171.98
Other Operating Expense-4.40-12.200.000.000.000.000.000.0019.34
Operating Income249.35856.51-146.75-349.40-439.93-374.94-302.48-192.80-115.69
Interest Expense198.56152.23166.99129.1890.8786.0256.3512.4912.55
Unusual Expense120.92-10.43155.82227.6624.7212.21129.2948.36-
Net Income Before Taxes-85.09696.62-363.12-696.11-587.49-518.34-402.93-239.93-128.11
Income Taxes20.8813.970.18-69.51-28.475.5635.2311.65-0.03
Consolidated Net Income-105.97682.64-363.30-626.60-559.02-523.90-438.16-251.58-128.08
Net Income From Continuing Operations-105.97682.64-363.30-626.60-559.02-523.90-438.16-251.58-128.08
Net Income-105.97682.64-363.30-626.60-559.02-523.90-438.16-251.58-128.08
EPS (Recurring)-0.247.70-3.31-6.24-7.55-7.31-5.27-3.70-2.75
EPS (Basic, Before Extraordinaries)-1.328.58-4.73-8.37-7.79-7.43-6.64-4.27-2.75
EPS (Diluted)-1.417.78-4.73-8.37-7.79-7.43-6.64-4.27-2.75
EBITDA310.36895.32-71.08-112.81-311.09-303.42-252.90-156.74-89.60
Non-Operating Income (Expense)-14.96-18.09106.4410.13-31.98-45.1785.1913.720.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense70.3658.8958.9580.2987.1675.5651.3430.7626.27
Price To Sales Ratio4.683.884.302.203.925.2110.589.216.04
Gross Margin89.2895.8585.3669.2876.9383.8385.3487.0486.57
Operating Margin21.5849.49-18.19-37.26-62.95-69.62-79.44-62.80-43.70
Net Margin-9.1739.44-45.03-66.81-80.00-97.27-115.07-81.95-48.38
Shares Outstanding83.5481.4777.7075.7173.1070.8369.7261.9450.61
Market Capitalization5,358.535,358.533,481.432,079.762,743.742,815.904,164.422,960.141,731.62

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue357.81360.52272.55164.68211.01178.881,176.10213.17
Cost of Goods Sold Incl. D&A36.2631.7639.6116.3023.3215.4816.6619.59
Gross Profit321.55328.76232.94148.38187.69163.391,159.44193.58
Selling, General and Administrative Excl. Other185.43179.78187.86233.60185.00204.15191.83209.45
Research and Development105.3599.15100.87133.13100.16112.99108.97124.77
Other Operating Expense0.000.00-0.80-3.60-0.80-5.90-1.900.00
Operating Income136.11148.9845.89-81.623.49-34.86969.50-15.87
Interest Expense45.8748.4849.0355.1932.5930.3634.0941.06
Unusual Expense130.260.000.93-10.280.470.10-0.72146.52
Net Income Before Taxes-41.0997.55-2.46-139.08-23.07-71.05929.83-94.70
Income Taxes10.6114.050.35-4.12-38.97-6.2063.27-28.81
Consolidated Net Income-51.6983.50-2.81-134.9715.90-64.85866.56-65.89
Net Income From Continuing Operations-51.6983.50-2.81-134.9715.90-64.85866.56-65.89
Net Income-51.6983.50-2.81-134.9715.90-64.85866.56-65.89
EPS (Recurring)0.470.92-0.03-1.760.20-0.8310.040.48
EPS (Basic, Before Extraordinaries)-0.621.01-0.03-1.670.20-0.8311.09-0.85
EPS (Diluted)-0.620.92-0.03-1.670.20-0.8310.04-0.85
EBITDA152.93164.8561.30-68.7214.60-27.27976.72-9.11
Non-Operating Income (Expense)-1.07-2.951.61-12.556.50-5.74-6.30108.75
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense18.8218.4018.5014.6315.3514.6514.2713.62
Price To Earnings Ratio--8.818.888.807.50--
Price To Sales Ratio4.687.446.803.543.002.162.484.32
Gross Margin89.8791.1985.4790.1088.9591.3598.5890.81
Operating Margin38.0441.3216.84-49.571.65-19.4982.43-7.45
Net Margin-14.4523.16-1.03-81.967.53-36.2573.68-30.91
Shares Outstanding83.5483.3382.8881.4779.9379.3879.2377.70
Market Capitalization5,358.536,766.175,639.446,098.704,875.123,870.914,019.183,481.43

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1,945.371,139.70876.74410.70773.381,103.65686.56227.59191.25
Short Term Receivables181.62158.55161.02155.61110.4569.9355.5467.9140.39
Inventories79.6523.1930.5821.8115.8618.7019.2916.1210.75
Other Current Assets67.3144.09150.29105.6654.6839.4717.909.256.67
Total Current Assets2,273.951,365.531,218.63693.78954.371,231.74779.28320.86249.06
Net Property, Plant & Equipment135.42117.66178.99175.02130.01118.2435.2412.698.38
Total Investments and Advances13.6915.6116.2816.097.507.507.500.000.00
Intangible Assets471.09201.13461.84788.23807.18797.67792.84783.37132.99
Deferred Tax Assets12.4811.747.48------
Other Assets4.625.1019.9632.4939.0053.128.912.301.22
Total Assets2,911.251,716.761,903.181,705.621,938.062,208.281,623.781,119.22391.65
Short Term Debt Incl. Current Port. of LT Debt302.1213.3616.0012.37159.818.7425.1511.670.00
Accounts Payable45.4917.276.0427.2723.0318.6610.326.0015.28
Income Tax Payable4.684.700.004.711.294.32---
Other Current Liabilities616.15545.64581.05361.89325.21245.61200.38149.1366.77
Total Current Liabilities968.43580.98603.10406.24509.35277.33235.86166.8082.05
Long Term Debt96.58375.93399.02691.26375.57411.70302.88141.35144.97
Provision for Risks Charges0.000.000.00164.00239.90240.40356.30328.540.00
Deferred Tax Liabilities12.4811.7463.39102.83137.11136.74130.86122.03-
Other Liabilities2,039.071,846.181,656.22688.38674.69660.133.569.788.20
Total Liabilities3,116.562,814.842,721.742,052.701,936.621,726.301,029.45768.50235.22
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-205.31-1,098.07-818.55-347.091.44481.98594.33350.73156.44
Total Shareholders Equity-205.31-1,098.07-818.55-347.091.44481.98594.33350.73156.44
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-205.31-1,098.07-818.55-347.091.44481.98594.33350.73156.44
Total Liabilities & Stockholders Equity2,911.251,716.761,903.181,705.621,938.062,208.281,623.781,119.22391.65
Book Value Per Share-2.52-14.13-10.81-4.750.026.919.606.933.76
Tangible Book Value Per Share-8.30-16.72-16.91-15.53-11.38-4.53-3.21-8.550.56
Full-Time Employees9919399951,4101,177967761517373
Price to Book Ratio-28.02-3.29-3.10-12.091,962.078.835.014.954.74
Return on Assets29.50-20.07-34.73-30.68-25.27-22.87-18.34-16.95-23.90
Return on Equity-----216.75-81.42-53.24-50.51-57.24
Return on Invested Capital----162.42-138.96-49.03-28.04-26.03-26.21
Quick Ratio2.272.311.971.651.844.373.221.832.90
Current Ratio2.352.352.021.711.874.443.301.923.04

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-105.97682.64-363.30-626.60-559.02-523.90-438.16-251.58-128.08
Depreciation61.0138.8175.66236.59138.7271.5249.5735.8926.09
Other Funds (Non Cash)78.8642.30135.11282.53192.85224.46151.7387.7960.14
Funds from Operations33.90763.76-208.43-154.41-261.72-227.54-230.98-119.07-41.85
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-23.41-52.56100.74-4.00-94.94-23.7936.9120.4314.21
Cash from Operating Activities10.49711.20-107.69-158.42-356.65-251.33-194.07-98.64-27.64
Capital Expenditures-51.81-300.01-74.25-120.62-152.46-85.33-55.98-45.44-15.53
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-48.89
Sale of Fixed Assets and Businesses0.000.0728.060.000.000.000.000.000.00
Purchase or Sale of Investments-572.88-562.04-69.62-56.12442.64304.51-495.57-341.8021.81
Purchase of Investments-2,033.11-1,417.16-667.36-212.48-75.55-543.27-1,439.66-498.07-68.61
Sale Or Maturity of Investments1,460.23855.12597.74156.37518.19847.78944.09156.2790.42
Other Uses0.000.000.000.000.000.00-10.000.000.00
Other Sources0.000.00160.000.000.000.000.000.000.00
Cash from Investing Activities-624.70-861.9844.18-176.74290.18219.18-561.55-387.24-42.61
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock90.6599.0533.7629.9971.0823.10103.57345.61131.57
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock90.6599.0533.7629.9971.0823.10103.57345.61131.57
Proceedsfrom Stock Options0.000.000.000.0050.000.0028.09323.76117.92
Issuance or Reduction of Debt, Net116.900.000.00-381.93137.27-2.22-46.16267.600.00
Change in Long Term Debt116.900.000.00-381.93137.27-2.22-46.16267.600.00
Issuance of Long Term Debt547.000.000.000.00288.550.000.00279.270.00
Reduction of Long Term Debt-430.100.000.00-381.93-151.28-2.22-46.16-11.670.00
Net Financing Active Other Cash Flow240.00233.66223.591,000.00-40.400.00611.300.000.00
Other Financing Activities Uses0.00-6.34-18.200.00-40.400.00-38.70-0.00
Cash from Financing Activities447.55331.09255.87646.40167.9520.88668.72613.21131.57
Exchange Rate Effect5.7022.71-7.333.11-2.77-7.827.69-1.30-3.61
Net Change in Cash-160.97203.02185.03314.3698.71-19.09-79.22126.0357.71
Free Cash Flow2.07702.34-114.19-186.86-388.67-279.55-211.91-112.40-34.74
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow2,616.159.55-------
Deferred Taxes & Investment Tax Credit--0.00-55.91-46.93-34.280.385.878.830.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments2,127.922,229.081,892.461,945.371,687.821,989.15
Short Term Receivables238.07239.04219.92181.62203.07196.13
Inventories109.3391.3575.5779.6552.6934.06
Other Current Assets62.4757.8866.0567.3164.2253.53
Total Current Assets2,537.782,617.362,254.002,273.952,007.802,272.88
Net Property, Plant & Equipment122.28126.27129.43135.42137.65113.35
Total Investments and Advances16.4416.4516.4513.6913.6815.68
Intangible Assets526.03485.27463.02471.09478.81226.15
Deferred Tax Assets---12.48--
Other Assets5.185.146.204.625.756.10
Total Assets3,207.723,250.482,869.102,911.252,643.702,634.16
Short Term Debt Incl. Current Port. of LT Debt14.2173.42305.01302.12300.8117.08
Accounts Payable41.5940.4525.4845.4936.6226.50
Income Tax Payable0.000.000.004.682.9339.92
Other Current Liabilities720.27657.21593.11616.15525.90544.30
Total Current Liabilities776.08771.07923.60968.43866.25627.81
Long Term Debt621.82623.0590.0796.58109.32371.08
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---12.48--
Other Liabilities2,001.032,021.722,035.892,039.071,823.891,841.81
Total Liabilities3,398.923,415.843,049.573,116.562,799.462,840.70
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-191.21-165.36-180.47-205.31-155.76-206.55
Total Shareholders Equity-191.21-165.36-180.47-205.31-155.76-206.55
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-191.21-165.36-180.47-205.31-155.76-206.55
Total Liabilities & Stockholders Equity3,207.723,250.482,869.102,911.252,643.702,634.16
Book Value Per Share-2.29-1.98-2.18-2.52-1.95-2.60
Tangible Book Value Per Share-8.59-7.81-7.76-8.30-7.94-5.45
Full-Time Employees---991--
Price to Book Ratio-28.02-37.46-27.04-38.98-23.59-20.83
Return on Assets-3.62-1.30-6.7629.5033.5127.65
Return on Invested Capital-12.0018.24----39.41
Quick Ratio3.133.282.362.272.263.57
Current Ratio3.273.392.442.352.323.62

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-51.6983.50-2.81-134.9715.90-64.85
Depreciation16.8215.8715.4112.9011.117.58
Other Funds (Non Cash)23.5819.5539.06-3.32-8.4315.65
Funds from Operations-11.30118.9351.66-125.3918.57-41.61
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-14.0110.19-110.7091.11-84.88-16.72
Cash from Operating Activities-25.31129.11-59.04-34.27-66.30-58.33
Capital Expenditures-6.02-7.14-1.35-37.29-256.19-3.99
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-436.39-115.41-92.3871.30-33.43-418.01
Purchase of Investments-759.14-475.99-478.63-319.35-233.61-536.65
Sale Or Maturity of Investments322.75360.58386.24390.65200.18118.63
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-442.41-122.56-93.7434.01-289.62-422.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock5.3516.406.4062.5016.833.96
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.3516.406.4062.5016.833.96
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-78.58195.480.000.000.000.00
Change in Long Term Debt-78.58195.480.000.000.000.00
Issuance of Long Term Debt10.75536.250.000.000.000.00
Reduction of Long Term Debt-89.33-340.770.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00240.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-73.24211.886.40302.5015.223.96
Exchange Rate Effect-0.04-2.54-1.529.79-6.0613.59
Net Change in Cash-541.00215.90-147.90312.03-346.77-462.79
Free Cash Flow-27.97126.92-60.24-36.65-69.75-59.65
Price to Free Cash Flow2,616.15--8.737.585.47

Revenue breakdown

Collaboration and License2024: 304.00K 2025: 998.36M
Manufacturing2024: 1.66M
Product2024: 582.15M 2025: 586.70M
Royalty2024: 203.86M 2025: 244.22M
Translarna2024: 18.81M 2025: -98.63M
Non-US2024: 393.74M
United States2024: 413.04M 2025: 1.73B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.61%7.8M81.0M1.11M
2026-10-1510.27%8.3M80.9M1.13M
2026-09-3011.34%9.2M80.9M1.28M
2026-09-1512.05%9.7M80.8M1.56M
2026-08-3112.32%9.8M79.8M1.66M
2026-08-1412.82%10.2M79.7M1.69M
2026-07-3113.11%10.6M80.6M1.83M
2026-07-1512.27%9.8M80.1M1.82M
2026-06-3021.61%17.3M80.1M1.60M
2026-06-1514.71%11.8M80.1M1.27M
2026-05-2913.32%10.7M80.1M1.22M
2026-05-1512.78%10.2M80.1M1.27M
2026-04-3012.21%9.8M79.9M1.15M
2026-04-1511.35%8.5M75.3M1.11M
2026-03-3112.55%9.5M75.3M1.25M
2026-03-1311.75%8.8M75.3M1.25M
2026-02-2712.77%9.6M75.3M1.29M
2026-02-1312.74%9.6M75.3M1.56M
2026-01-3013.09%10.1M77.0M1.62M
2026-01-1513.37%10.3M77.0M1.57M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call35.0027.6031.600.003.6590.000.000.908-0.3600.017
call40.0022.7026.700.002.9710.000.000.889-0.3430.019
call45.0017.7021.500.002.4150.000.000.865-0.3230.022
call50.0012.7016.400.001.8600.000.000.831-0.3000.025
call55.007.9011.7010.561.4931.000.000.781-0.2730.030
call60.003.107.004.101.0913.000.000.695-0.2350.035
call65.000.003.205.350.82714.000.000.514-0.1940.040
call70.000.052.401.331.0933120.000.353-0.2330.037
call75.000.002.250.601.4283030.000.282-0.2740.034
call80.000.002.151.171.6693.000.000.244-0.2980.032
call85.000.002.150.001.9140.000.000.222-0.3220.030
call90.000.002.150.002.1290.000.000.206-0.3460.029
call95.000.002.150.352.3461.000.000.193-0.3660.028
put35.000.002.150.003.7980.000.00-0.092-0.3540.017
put40.000.002.150.103.1484.000.00-0.112-0.3370.019
put45.000.002.150.002.5830.000.00-0.135-0.3170.022
put50.000.002.150.602.0700.000.00-0.169-0.2950.025
put55.000.002.300.101.60226.000.00-0.219-0.2670.030
put60.000.002.550.621.1773140.00-0.308-0.2300.035
put65.000.003.501.000.8603040.00-0.486-0.1870.040
put70.003.907.704.501.1001.000.00-0.646-0.2250.038
put75.008.6012.400.001.3950.000.00-0.715-0.2630.034
put80.0013.6017.4020.771.6572.000.00-0.755-0.2890.032
put85.0018.6022.400.001.9130.000.00-0.778-0.3150.030
put90.0023.6027.400.002.1420.000.00-0.794-0.3370.029
put95.0028.6032.400.002.3500.000.00-0.807-0.3560.028

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-09144Filing for proposed sale of securities under Rule 144.SEC
2026-10-094Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-10-07144Filing for proposed sale of securities under Rule 144.SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-09-218-KCurrent report2026-09-21SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-288-KCurrent report2026-08-25SEC
2026-08-25144/ASEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-138-KCurrent report2026-08-12SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-28SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000452.65K5
2026-09003.48M5
2026-08004.52M6
2026-07006.45M6
2026-06008.78M7
2026-05001.40M3
2026-04004.01M4
2026-03002.52M5
2026-02002.11M10
2026-01004.70M28
2025-12005.81M6
2025-110012.54M7

Institutional holders

Manager% owned
Ovata Capital Management Ltd16.97%
BlackRock, Inc.16.84%
RTW INVESTMENTS, LP9.34%
Jupiter Topco LLC8.72%
VANGUARD PORTFOLIO MANAGEMENT LLC5.94%
STATE STREET CORP5.54%
WELLINGTON MANAGEMENT GROUP LLP4.98%
VANGUARD CAPITAL MANAGEMENT LLC4.51%
TORONTO DOMINION BANK2.61%
GEODE CAPITAL MANAGEMENT, LLC2.57%

Funds

Fund% owned
Franklin Convertible Securities Fund41.11%
Columbia Convertible Securities Fund16.59%
iShares Convertible Bond ETF14.93%
State Street(R) SPDR(R) Bloomberg Convertible Securities ETF10.13%
Lord Abbett Convertible Fund8.39%
iShares Core S&P Small-Cap ETF6.02%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.18%
VANGUARD HEALTH CARE FUND2.79%
iShares Russell 2000 ETF2.57%
WESTWOOD ALTERNATIVE INCOME FUND2.41%

OakChart. PTCT. Cached 15 minutes.